EUVIMEDOpdag EUVIMED
Open access

Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection

Nicole M Ondrush iD, Meenakshi Rana iD, Gopi Patel, Rachel Chasan, Timothy Sullivan iD

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70630 ↗

At a glance

Journal article in Clinical Transplantation, 2026. Written by Nicole M Ondrush and 4 co-authors. Institution: Department of Pharmacy, The Mount Sinai Hospital, New York, New York, USA. Major MEDLINE topics: Caliciviridae Infections, Organ Transplantation, Norovirus, Immunoglobulins. 19 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Norovirus gastroenteritis can cause serious complications in solid organ transplant (SOT) recipients, and no licensed treatment is available. Typical therapy is supportive care; however, some medications may be used off‐label. Serum‐derived bovine immunoglobulin (IG), a medical food product, has been utilized off‐label for norovirus gastroenteritis, although clinical efficacy is uncertain. The objective of this study was to evaluate the outcomes of SOT recipients who received serum‐derived bovine IG for the treatment of norovirus.

Methods

Adult SOT recipients, who received serum‐derived bovine IG as treatment for norovirus between January 2020 and December 2024, were evaluated for inclusion. Outcomes evaluated included improvement in the number of bowel movements to less than three per day, presence of more formed bowel movements, presence of acute kidney injury (AKI), initial response rates, and 90‐day relapse‐free rate.

Results

14 SOT recipients were included. Nine patients had a history of prior norovirus gastroenteritis. Reduction to less than three bowel movements per day occurred in 8/14 (57%) patients. Overall, 12/14 (86%) patients experienced clinical improvement after a median of 4.5 days of serum‐derived bovine IG. Of those alive at 90‐day follow‐up, 8 of 10 (80%) did not experience relapsing norovirus infection.

Conclusion

Orally administered serum‐derived bovine IG may be a potential option for SOT recipients with chronic norovirus infection. Larger, well‐designed studies are needed to further define its clinical efficacy.

Subjects

MeSH terms (MEDLINE)

Caliciviridae InfectionsOrgan TransplantationNorovirusImmunoglobulinsGastroenteritisHumansCattleAnimalsMaleFemaleFollow-Up StudiesPrognosisAdministration, OralRetrospective StudiesTransplant Recipients

Author keywords

immunoglobulinnorovirussolid organ transplant

Substances

Immunoglobulins

Authors and institutions

  • Department of Pharmacy, The Mount Sinai Hospital, New York, New York, USA.
  • Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID profiles: Nicole M Ondrush, Meenakshi Rana, Timothy Sullivan

Cite

APA

Ondrush, N. M., Rana, M., Patel, G., Chasan, R., & Sullivan, T. (2026). Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection. Clinical Transplantation. https://doi.org/10.1111/ctr.70630

Vancouver

Ondrush NM, Rana M, Patel G, Chasan R, Sullivan T. Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection. Clinical Transplantation. 2026. doi:10.1111/ctr.70630

BibTeX
@article{Ondrush2026,
  author = {Ondrush, Nicole M and Rana, Meenakshi and Patel, Gopi and Chasan, Rachel and Sullivan, Timothy},
  title = {Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70630}
}
Start for free →